Cylert Related Published Studies
Well-designed clinical trials related to Cylert (Pemoline)
A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents. [2004.04]
Effect of fluoxetine, pemoline and placebo on heart period and QT variability in normal humans. [2003.09]
Pemoline treatment of adolescents with attention deficit hyperactivity disorder: a short-term controlled trial. [2000.09]
Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder. [1999.06]
Intensive and sustained air operations: potential use of the stimulant, pemoline. [1998.07]
The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. [1996.02]
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. [1995.11]
A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. [1992.08]
Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. [1990.08]
Well-designed clinical trials possibly related to Cylert (Pemoline)
Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. [2005.02]
Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. [2004.06]
Stimulant treatment of adult attention-deficit/hyperactivity disorder. [2004.06]
Attention-deficit/hyperactivity disorder: cognitive evoked potential (P300) topography predicts treatment response to methylphenidate. [2004.01]
Approximate entropy of symptoms of mood: an effective technique to quantify regularity of mood. [2003.08]
Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. [2002.08]
Practice parameters for the treatment of narcolepsy: an update for 2000. [2001.06.15]
A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. [2001.02.12]
Psychopharmacologic treatment of acquired attention disorders in children with brain injury. [1998.09]
Treatment modalities for narcolepsy. [1998.02]
National Institute of Mental Health Collaborative Multimodal Treatment Study of Children with ADHD (the MTA). Design challenges and choices. [1997.09]
Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder. [1996.02]
Psychostimulant effects on academic and behavioral measures for ADHD junior high school students in a lecture format classroom. [1991.10]
Other research related to Cylert (Pemoline)
Pemoline (2-amino-5-phenyl-1,3-oxazol-4-one)-induced self-injurious behavior: a rodent model of pharmacotherapeutic efficacy. [2008.01]
Efficacy of bupropion in the treatment of pemoline dependence. [2007.07]
Effectiveness of risk management plans: a case study of pemoline using pharmacy claims data. [2007.01]
A rare case of dependence on pemoline. [2006.09.30]
A study of compliance with FDA recommendations for pemoline (Cylert). [2002.07]
Inappropriate pemoline therapy leading to acute liver failure and liver transplantation. [2002.06]
Pemoline ingestion in children: a report of five cases and review of the literature. [2002.03]
Pemoline hepatotoxicity and postmarketing surveillance. [2001.06]
Severe hypotension in a patient receiving pemoline during general anesthesia. [2000.11]
Response to growth hormone in attention deficit hyperactivity disorder: effects of methylphenidate and pemoline therapy. [1998.08]
Pemoline hepatotoxicity in children. [1998.05]
Pemoline therapy resulting in liver transplantation. [1998.04]
Pemoline toxicosis in a dog. [1998.01.01]
Effects of pemoline on spontaneous and event-related electrical activity of the brain. [1998]
Pemoline in adult attention deficit hyperactivity disorder: predictors of nonresponse. [1997.03]
Pemoline-associated hepatic failure: a critical analysis of the literature. [1997.01]
Pemoline induced acute choreoathetosis: case report and review of the literature. [1997]
Pemoline-induced autoimmune hepatitis. [1996.10]
An open trial of pemoline in drug-dependent delinquents with attention-deficit hyperactivity disorder. [1996.08]
Pemoline for the treatment of cocaine dependence in methadone-maintained patients. [1996.07]
Pemoline therapy in college students with attention deficit hyperactivity disorder: a retrospective study. [1996.07]
Pemoline effects on children with ADHD: a time-response by dose-response analysis on classroom measures. [1995.11]
Abnormal auditory P300 topography in attention deficit disorder predicts poor response to pemoline. [1995.10]
Pemoline-associated fulminant liver failure: testing the evidence for causation. [1995.06]
Pharmacodynamics of pemoline in attention deficit disorder with hyperactivity. [1992.03]
Combination of fluoxetine with pemoline in the treatment of major depressive disorder. [1991.06]
Pemoline-associated hepatic injury. [1990.11]
Hepatotoxicity due to pemoline (Cylert): a report of two cases. [1990.02]
Pemoline-induced abnormal involuntary movements. [1989.04]
Pemoline-induced choreoathetosis and rhabdomyolysis. [1988.01]
Other possibly related research studies
[Attention deficit hyperactivity disorder: pharmacological options that are not "Ritalin"] [2005.08]
Pharmacologic management of daytime sleepiness. [2004]
Efficacy of stimulants in adult ADHD. [2003.12]
Efficacy and safety of modafinil for improving daytime wakefulness in patients treated previously with psychostimulants. [2003.01]
Psychosocial treatments for attention-deficit/hyperactivity disorder in children. [2002]
Management of ADHD in adults. [2002]
Fatigue in multiple sclerosis. [2001.05]
Medical and nonmedical stimulant use among adolescents: from sanctioned to unsanctioned use. [2001.10.16]
Emergence of tics in children with attention deficit hyperactivity disorder treated with stimulant medications. [2001.05]
Treatments for fatigue in multiple sclerosis: a rapid and systematic review. [2000]
Psychostimulants in supportive care. [2000.09]
Treatment of attention-deficit/hyperactivity disorder. [1999.11]
Psychotic side effects of psychostimulants: a 5-year review. [1999.10]
['Fatigue' in multiple sclerosis] [1999.06]
Drug interactions with psychostimulants. [1999.01]
The use of psychostimulants in the pediatric patient. [1998.10]
Pharmacotherapy of attention-deficit/hyperactivity disorder in adults. [1998]
Psychopharmacology of ADHD: children and adolescents. [1998]
Attention-deficit/hyperactivity disorder: a life-span perspective. [1998]
Dopaminergic agents and stimulants as antidepressant augmentation strategies. [1998]
Prolonged P300 latency in attention deficit hyperactivity disorder predicts poor response to imipramine. [1996.10]
Alertness-enhancing drugs as a countermeasure to fatigue in irregular work hours. [1997.03]
Compliance with stimulant medications in patients with narcolepsy. [1997.01]
Narcolepsy. [1996.09]
Pediatricians' knowledge and attitudes concerning diagnosis and treatment of attention deficit and hyperactivity disorders. A national survey approach. [1995.11]
Disruptive behavior, hyperactivity, and learning disabilities in children with Tourette's syndrome. [1995]
Evaluation of treatment with stimulants in narcolepsy. [1994.12]
Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder. [1994.08]
Application of actigraphy in the clinical setting: use in children with attention-deficit hyperactivity disorder. [1994.03]
Dyskinesias possibly induced by norpseudoephedrine. [1994.01]
Drug treatment for hyperactive children. Therapeutic guidelines. [1993.11]
Evaluating and managing attention deficit disorder in children who are deaf or hard of hearing. [1993.10]
Dramatic favorable responses of children with learning disabilities or dyslexia and attention deficit disorder to antimotion sickness medications: four case reports. [1991.12]
Relative efficacy of drugs for the treatment of sleepiness in narcolepsy. [1991.06]
CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. [1991.04]
Social impact of stimulant treatment for hyperactive children. [1991.04]
Effects of stimulant medication on learning in children with ADHD. [1991.04]
Stimulant medication and parent training therapies for attention deficit-hyperactivity disorder. [1991.04]
Cognitive training in ADHD children: less to it than meets the eye. [1991.04]
[Hyperkinetic disorders with attention deficit. Diagnostic and therapeutic approach] [1991]
Attention deficit hyperactivity disorder: does it affect adults too? [1990.12]
Psychostimulants in psychiatry. [1990.02]
Stimulant medication and short attention span: a clinical approach. [1989.12]
Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder. [1989.10]
The relationship between stimulant medication and tics. [1988.06]
Modafinil for the treatment of diminished responsiveness in a patient recovering from brain surgery. [2005.08.20]
Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. [2005.06]
Multiple sclerosis-related fatigue. [2005.05]
Fatigue in multiple sclerosis: a rational approach to evaluation and treatment. [2005.03]
|
